> DFF – 4004-00022
The Danish Council for Independent Research | Medical Sciences: DFF – 4004-00022, October 1st, 2014 – September 30th, 2017

Project: Therapeutic management of patients with hepatocellular carcinoma: Clinical impact of 18F-deoxy-galactose PET/CT molecular imaging

Participants: Susanne Keiding, Michael Sørensen, Gerda Elisabeth Villadsen, Kirstine Petrea Bak-Fredslund

Project Summary: The outcome of intended curative treatment of hepatocellular carcinoma (HCC) is burdened by reappearance of tumours and metastases, primarily due to poor sensitivity of today’s diagnostic imaging tests. Based on encouraging results of a proof-of-concept study using positron emission tomography (PET) with 18F-flouro-deoxy-D-galactose (18F-FDGal) in patients clinically suspected for or with known HCC, concerning both detection of hepatic and extrahepatic tumours, and subsequent clinical use in 45 patients being referred to 18F-FDGal PET/CT because of uncertain results of conventional contrast-enhanced CT, we will test the diagnostic and therapy-monitoring value of 18F-FDGal PET/CT for HCC in a large-scale controlled prospective clinical study of 120 patients. Worldwide HCC causes about 500,000 deaths per year, and if our initial results are confirmed, we foresee a breakthrough for therapy and survival of patients with HCC worldwide.